𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

✍ Scribed by Kenneth Rockwood; Sherri Fay; Mary Gorman; Daniel Carver; Janice E Graham

Book ID
115009472
Publisher
BioMed Central
Year
2007
Tongue
English
Weight
272 KB
Volume
7
Category
Article
ISSN
1471-2377

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The ADAS-cog and clinically meaningful c
The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
✍ Kenneth Rockwood; Sherri Fay; Mary Gorman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

## Abstract ## Background A minimum 4‐point change at 6 months on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog) is deemed clinically important, but this cut‐point has been little studied in relation to clinical meaningfulness. In an investigator‐initiated, clinical trial o

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##